BridgeBio Pharma has flipped its positioning story in 48 hours — shorts are covering at pace, analysts are lifting targets in unison, and the options tape has swung from extreme bullishness to a defensive pulse that deserves a closer look.
The most striking development this week is the sharp short-covering that followed Monday's earnings print. Short interest dropped 11.4% in a single session on August 11, falling to 12% of the free float from roughly 13.5% just days prior. That unwind erased roughly 3 million shares of short exposure and brings the position back toward levels last seen in early July. The move confirms that at least some of the bear case has been unwound post-results — not routed, but meaningfully trimmed. Borrow conditions give little reason to hold the short: cost to borrow is at just 0.42%, barely above the month's lows, and availability is extraordinarily loose at 1,340% — meaning there are roughly 13 shares available to lend for every one currently borrowed. The lending market imposes no pressure on short holders.
The options market tells a different story from the pre-earnings note. Two days ago the put/call ratio was hugging the 52-week floor at 0.19 — the market was aggressively bullish into the print. It has now jumped to 1.10, nearly at the 52-week high of 1.17 and almost three standard deviations above its 20-day average of 0.29. That is a striking reversal in a single session. Some of this reflects mechanical post-earnings repositioning as call contracts expired or were closed, but a reading this elevated suggests fresh put buying or call liquidation — the tape has flipped from leaning on upside to hedging against further slippage.
The Street, by contrast, is firmly in the bull camp. Eight firms raised price targets in the two days following results, all while maintaining positive ratings. JP Morgan lifted its target to $111 from $100, keeping its Overweight. TD Cowen moved to $110 from $95. Piper Sandler sits at $115. The lone exception was Morgan Stanley, which trimmed its target by a single dollar to $97, a token cut that barely dents the bullish consensus. The mean target across the group stands at $108, implying roughly 29% upside to the current $83.70 price. Factor scores reinforce the macro analyst view: forward EPS growth ranks in the 87th percentile and earnings surprise history sits at the 82nd — BBIO has consistently beaten estimates. Bulls point to acoramidis building momentum in ATTR-CM and a pipeline approaching a blockbuster revenue run rate. Bears remain focused on execution risk, competitive pressure from injectable rivals, and the dilution tail from prior financing activity.
Institutional flows add some nuance to the ownership picture. Farallon added 1.4 million shares through June 30, and BlackRock added nearly 920,000 as recently as July 31 — both meaningful additions at current prices. Viking Global, however, trimmed 2 million shares in early July. CEO-adjacent insider data shows director Jennifer Cook sold over $13 million worth of stock across two July 9 transactions at prices between $84 and $90 — levels close to or above where the stock trades today. Those sales were almost certainly pre-planned, but the volume and price are worth noting.
The next earnings event is pencilled in for October 30. Between now and then, the question is whether the sharp PCR spike on August 11 marks a one-session defensive flush — the same pattern that appeared briefly on July 31 before fully reversing — or whether post-earnings positioning is genuinely more cautious this time. The divergence between an analyst community that just lifted targets across the board and an options market that bought puts aggressively on the same day is the tension worth tracking into next week.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
